(c) 2024 PillSync.com

clomipramine hydrochloride 50 mg

INDICATIONS AND USAGE Clomipramine hydrochloride capsules, USP are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM-III-R (circa 1989) diagnosis of OCD. Obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. Compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. The effectiveness of clomipramine hydrochloride for the treatment of OCD was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. Patients in all studies had moderate-to-severe OCD (DSM-III), with mean baseline ratings on the Yale-Brown Obsessive Compulsive Scale (YBOCS) ranging from 26 to 28 and a mean baseline rating of 10 on the NIMH Clinical Global Obsessive Compulsive Scale (NIMH-OC). Patients taking clomipramine experienced a mean reduction of approximately 10 on the YBOCS, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. Clomipramine-treated patients experienced a 3.5 unit decrement on the NIMH-OC. Patients on placebo showed no important clinical response on either scale. The maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents. The effectiveness of clomipramine hydrochloride for long-term use (i.e., for more than 10 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to use clomipramine hydrochloride for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ).

upsher-smith laboratories, llc


2 years ago CAPSULE TURQUOISE 0631 50mg clomipramine hydrochloride 50 mg

CAPSULE TURQUOISE 0631 50mg

HOW SUPPLIED

CLOMIPRAMINE HYDROCHLORIDE capsules, USP

CLOMIPRAMINE HYDROCHLORIDE capsules, USP 25 mg are orange opaque cap & white opaque body, printed with “0630 25mg” on the body in black ink. They are supplied as follows: NDC 0832-0630-11 bottles of 100 NDC 0832-0630-10 bottles of 1000

CLOMIPRAMINE HYDROCHLORIDE capsules, USP 50 mg are aqua blue opaque cap & white opaque body, printed with “0631 50mg” on the body in black ink. They are supplied as follows: NDC 0832-0631-11 bottles of 100 NDC 0832-0631-10 bottles of 1000

CLOMIPRAMINE HYDROCHLORIDE capsules, USP 75 mg are yellow opaque cap & white opaque body, printed with “0632 75mg” on the body in black ink. They are supplied as follows: NDC 0832-0632-11 bottles of 100 NDC 0832-0632-10 bottles of 1000 Storage – Store at 20º to 25ºC (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container, with a child-resistant closure, as required.


More pills like CAPSULE 0631 50mg

Related Pills

clomipramine hydrochloride 75 mg

upsher-smith laboratories, llc

clomipramine hydrochloride 25 mg

upsher-smith laboratories, llc












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site